Literature DB >> 14605243

Insulin autoantibody isotypes during the prediabetic process in young children with increased genetic risk of type 1 diabetes.

Sanna Hoppu1, Matti S Ronkainen, Teija Kimpimäki, Satu Simell, Sari Korhonen, Jorma Ilonen, Olli Simell, Mikael Knip.   

Abstract

This work aimed to assess the maturation of the humoral immune response to insulin in preclinical type 1 diabetes by observing the emergence of various isotypes of insulin autoantibodies (IAA) in children with HLA-DQB1-conferred disease susceptibility. The series was derived from the Finnish Type 1 Diabetes Prediction and Prevention Study and comprised 15 IAA-positive children who presented with type 1 diabetes during prospective observation (progressors) and 30 children who remained nondiabetic (nonprogressors). An isotype-specific radiobinding assay was used to determine isotype-specific IAA (IgG1-4 and IgA) from samples obtained with an interval of 3-12 mo. The progressors had IAA of subclass IgG3 in their first IAA-positive sample more often than did the nonprogressors (13 of 15 versus 12 of 30; p = 0.003). Nine progressors had a dominant IgG1-IAA response initially, and six had a dominant IgG3-IAA response. The corresponding distribution among the nonprogressors was that 20 had a dominant IgG1-IAA response, none had an IgG3-IAA response, and three had a dominant response other than IgG1- or IgG3-IAA (chi(2)(df = 2) = 12.02; p = 0.002). The progressors had higher integrated levels (area under the curve) of IgG1-IAA (p = 0.05) and IgG3-IAA (p = 0.002). Nine progressors had a dominant integrated IgG1-IAA response and six had a dominant IgG3-IAA response over the observation period, whereas 22 nonprogressors had a dominant IgG1-IAA response, six had a dominant IgG2-IAA response, and one an IgG3-IAA response (chi(2)(df = 2) = 11.23; p = 0.004). Genetically susceptible young children who progress rapidly to clinical type 1 diabetes are characterized by strong IgG1 and IgG3 responses to insulin, whereas a weak or absent IgG3 response is associated with relative protection from disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14605243     DOI: 10.1203/01.PDR.0000100905.41131.3F

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  15 in total

1.  Longitudinal epitope analysis of insulin-binding antibodies in type 1 diabetes.

Authors:  T R Hall; J W Thomas; C J Padoa; C Torn; M Landin-Olsson; E Ortqvist; C S Hampe
Journal:  Clin Exp Immunol       Date:  2006-10       Impact factor: 4.330

Review 2.  Type 1 diabetes and polyglandular autoimmune syndrome: A review.

Authors:  Martin P Hansen; Nina Matheis; George J Kahaly
Journal:  World J Diabetes       Date:  2015-02-15

Review 3.  Humoral autoimmunity in type 1 diabetes: prediction, significance, and detection of distinct disease subtypes.

Authors:  Massimo Pietropaolo; Roberto Towns; George S Eisenbarth
Journal:  Cold Spring Harb Perspect Med       Date:  2012-10-01       Impact factor: 6.915

4.  Reversing Tolerance in Isotype Switch-Competent Anti-Insulin B Lymphocytes.

Authors:  Jonathan M Williams; Rachel H Bonami; Chrys Hulbert; James W Thomas
Journal:  J Immunol       Date:  2015-06-24       Impact factor: 5.422

Review 5.  Psychological impact of screening and prediction in type 1 diabetes.

Authors:  Suzanne Bennett Johnson
Journal:  Curr Diab Rep       Date:  2011-10       Impact factor: 4.810

6.  IA-2 antibody isotypes and epitope specificity during the prediabetic process in children with HLA-conferred susceptibility to type I diabetes.

Authors:  S Hoppu; T Härkönen; M S Ronkainen; S Simell; A Hekkala; A Toivonen; J Ilonen; O Simell; M Knip
Journal:  Clin Exp Immunol       Date:  2006-04       Impact factor: 4.330

Review 7.  Insulin as an autoantigen in NOD/human diabetes.

Authors:  Li Zhang; Maki Nakayama; George S Eisenbarth
Journal:  Curr Opin Immunol       Date:  2008-02       Impact factor: 7.486

8.  Effect of oral insulin on insulin autoantibody levels in the Diabetes Prevention Trial Type 1 oral insulin study.

Authors:  J M Barker; K K McFann; T Orban
Journal:  Diabetologia       Date:  2007-06-22       Impact factor: 10.122

Review 9.  Islet Autoantibodies.

Authors:  Vito Lampasona; Daniela Liberati
Journal:  Curr Diab Rep       Date:  2016-06       Impact factor: 4.810

10.  Impact of intranasal insulin on insulin antibody affinity and isotypes in young children with HLA-conferred susceptibility to type 1 diabetes.

Authors:  Samppa J Ryhänen; Taina Härkönen; Heli Siljander; Kirsti Näntö-Salonen; Tuula Simell; Heikki Hyöty; Jorma Ilonen; Riitta Veijola; Olli Simell; Mikael Knip
Journal:  Diabetes Care       Date:  2011-04-22       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.